Sound Bioventures
Sound Bioventures is a venture capital fund that invests in about-to-be-clinical and clinical-stage private biotherapeutics companies in Europe, the UK and the USA. The firm focuses on supporting development of novel medicines that address significant unmet medical needs, with an emphasis on specialty therapeutics and orphan/rare disease opportunities. Fund I reached a first close at €110 million and the firm operates with a Scandinavian base and a transatlantic footprint.
Sound Bioventures
Services
Equity investment and financing
Provides direct capital to private biotherapeutics companies (seed through clinical-stage), including participation in seed rounds and larger financings.
Scientific and commercial due diligence
In-house evaluation of scientific rationale and commercial potential to support investment decisions and portfolio strategy.
Board participation and governance support
Team members join company boards and provide ongoing governance, strategic direction and clinical development guidance.
Company creation and syndicate collaboration
Co-creation and early-stage company formation in collaboration with partners and anchor investors (example: launch of Breye Therapeutics with Novo Holdings).
Network and cross-Atlantic facilitation
Facilitates exchange of innovation, sector knowledge and capital between the Nordic region and the US/UK markets.
Equity investment and financing
Provides direct capital to private biotherapeutics companies (seed through clinical-stage), including participation in seed rounds and larger financings.
Scientific and commercial due diligence
In-house evaluation of scientific rationale and commercial potential to support investment decisions and portfolio strategy.
Board participation and governance support
Team members join company boards and provide ongoing governance, strategic direction and clinical development guidance.
Company creation and syndicate collaboration
Co-creation and early-stage company formation in collaboration with partners and anchor investors (example: launch of Breye Therapeutics with Novo Holdings).
Network and cross-Atlantic facilitation
Facilitates exchange of innovation, sector knowledge and capital between the Nordic region and the US/UK markets.
Portfolio
Announced dosing of first cohort in Phase 1 study of ABO21009 for rheumatoid arthritis (May 2025).
#Biopharmaceuticals (immunomodulation / autoimmune)
Developing AX-158, a first-in-class oral Nck SH3.1 domain inhibitor for T cell-mediated diseases; participated in a $26M financing (May 2022).
#Biopharmaceuticals (T cell-mediated diseases; immunomodulation)
Launched from stealth after EUR 4 million seed financing led by Novo Holdings and Sound Bioventures (Nov 2022); in-licensed danegaptide as lead compound; aims to develop oral small molecules for DR and AMD.
#Ophthalmology (retinal vascular diseases: diabetic retinopathy, age-related macular degeneration)
Listed in Sound Bioventures portfolio navigation.
#Biopharmaceuticals / therapeutics (renal indications)
Announced dosing of first cohort in Phase 1 study of ABO21009 for rheumatoid arthritis (May 2025).
#Biopharmaceuticals (immunomodulation / autoimmune)
Developing AX-158, a first-in-class oral Nck SH3.1 domain inhibitor for T cell-mediated diseases; participated in a $26M financing (May 2022).
#Biopharmaceuticals (T cell-mediated diseases; immunomodulation)
Launched from stealth after EUR 4 million seed financing led by Novo Holdings and Sound Bioventures (Nov 2022); in-licensed danegaptide as lead compound; aims to develop oral small molecules for DR and AMD.
#Ophthalmology (retinal vascular diseases: diabetic retinopathy, age-related macular degeneration)
Listed in Sound Bioventures portfolio navigation.
#Biopharmaceuticals / therapeutics (renal indications)